Skadden secured a summary judgment ruling for Watson Pharmaceuticals in a consolidated MDL brought by purchasers of AndroGel alleging that a 2006 settlement with generic drug companies was anti-competitive. After securing the dismissal of federal and state antitrust claims in 2010 (also handled by Skadden), private plaintiffs pushed forward on claims that the underlying patent litigation and settlement between the companies was a sham. On September 28, Judge Thomas W. Thrash of the U.S. District Court for the Northern District of Georgia agreed with Skadden’s motion that the underlying litigation was not objectively baseless.

BACK TO TOP